Levels and determinants of urinary cadmium in general population in Spain: Metal-MCC-Spain study.


Journal

Environmental research
ISSN: 1096-0953
Titre abrégé: Environ Res
Pays: Netherlands
ID NLM: 0147621

Informations de publication

Date de publication:
07 2022
Historique:
received: 26 10 2021
revised: 17 01 2022
accepted: 12 02 2022
pubmed: 22 2 2022
medline: 7 5 2022
entrez: 21 2 2022
Statut: ppublish

Résumé

Cadmium is a ubiquitous and persistent metal, associated with different harmful health effects and with increased morbidity and mortality. Understanding the main sources of exposure is essential to identify at risk populations and to design public health interventions. To evaluate cadmium exposure in a random-sample of general adult population from three regions of Spain, assessed by the urinary cadmium (U-Cd) concentration, and to identify its potential determinants and sex-specific differences, including sociodemographic, lifestyle and dietary factors. We measured U-Cd (μg/g creatinine) in single urine spot samples from 1282 controls enrolled in the multicase-control study in common tumors in Spain (MCC-Spain) with inductively coupling plasma-mass spectrometry equipped with an octopole reaction systems (ICP-ORS-MS). The association between sociodemographic, lifestyle, and dietary characteristics and U-Cd concentrations was evaluated using geometric mean ratios (GMR) estimated by multiple log-linear regression models. Overall, geometric mean U-Cd concentration was 0.40 (95%CI: 0.38, 0.41) μg/g creatinine. Levels were higher in women than in men (GMR]: 1.19; 95%CI: 1.07, 1.32), and increased with age in males (p These results confirmed that tobacco exposure is the main modifiable predictor of U-Cd concentrations, and remark that the role of dietary/sociodemographic factors on U-Cd levels may differ by sex.

Sections du résumé

BACKGROUND
Cadmium is a ubiquitous and persistent metal, associated with different harmful health effects and with increased morbidity and mortality. Understanding the main sources of exposure is essential to identify at risk populations and to design public health interventions.
OBJECTIVE
To evaluate cadmium exposure in a random-sample of general adult population from three regions of Spain, assessed by the urinary cadmium (U-Cd) concentration, and to identify its potential determinants and sex-specific differences, including sociodemographic, lifestyle and dietary factors.
MATERIALS AND METHODS
We measured U-Cd (μg/g creatinine) in single urine spot samples from 1282 controls enrolled in the multicase-control study in common tumors in Spain (MCC-Spain) with inductively coupling plasma-mass spectrometry equipped with an octopole reaction systems (ICP-ORS-MS). The association between sociodemographic, lifestyle, and dietary characteristics and U-Cd concentrations was evaluated using geometric mean ratios (GMR) estimated by multiple log-linear regression models.
RESULTS
Overall, geometric mean U-Cd concentration was 0.40 (95%CI: 0.38, 0.41) μg/g creatinine. Levels were higher in women than in men (GMR]: 1.19; 95%CI: 1.07, 1.32), and increased with age in males (p
CONCLUSION
These results confirmed that tobacco exposure is the main modifiable predictor of U-Cd concentrations, and remark that the role of dietary/sociodemographic factors on U-Cd levels may differ by sex.

Identifiants

pubmed: 35189102
pii: S0013-9351(22)00286-9
doi: 10.1016/j.envres.2022.112959
pii:
doi:

Substances chimiques

Cadmium 00BH33GNGH
Creatinine AYI8EX34EU

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

112959

Informations de copyright

Copyright © 2022 Elsevier Inc. All rights reserved.

Auteurs

Julia Blanco Muñoz (J)

Department of Environmental Health. Centro de Investigación en Salud Poblacional, Instituto Nacional de Salud Pública. Cuernavaca, Morelos, Mexico.

Virginia Lope (V)

Department of Epidemiology of Chronic Diseases, National Center for Epidemiology, Instituto de Salud Carlos III, Av/Monforte de Lemos, 5, 28029, Madrid, Spain; Consortium for Biomedical Research in Epidemiology & Public Health (CIBERESP), Instituto de Salud Carlos III. Av/Monforte de Lemos, 5, 28029, Madrid, Spain. Electronic address: vicarvajal@isciii.es.

Nerea Fernández de Larrea-Baz (N)

Department of Epidemiology of Chronic Diseases, National Center for Epidemiology, Instituto de Salud Carlos III, Av/Monforte de Lemos, 5, 28029, Madrid, Spain; Consortium for Biomedical Research in Epidemiology & Public Health (CIBERESP), Instituto de Salud Carlos III. Av/Monforte de Lemos, 5, 28029, Madrid, Spain.

José Luis Gómez-Ariza (JL)

Department of Chemistry, Faculty of Experimental Sciences, Campus El Carmen, University of Huelva. Research Center for Natural Resources, Health and the Environment, Campus El Carmen, University of Huelva, Av. del Tres de Marzo, 3, 21007, Huelva, Spain.

Trinidad Dierssen-Sotos (T)

Consortium for Biomedical Research in Epidemiology & Public Health (CIBERESP), Instituto de Salud Carlos III. Av/Monforte de Lemos, 5, 28029, Madrid, Spain; Universidad de Cantabria - IDIVAL, 39011, Santander, Spain.

Guillermo Fernández-Tardón (G)

Consortium for Biomedical Research in Epidemiology & Public Health (CIBERESP), Instituto de Salud Carlos III. Av/Monforte de Lemos, 5, 28029, Madrid, Spain; Institute of Health Research of the Principality of Asturias (ISPA)/University of Oviedo, 03301, Oviedo, Spain.

Nuria Aragonés (N)

Consortium for Biomedical Research in Epidemiology & Public Health (CIBERESP), Instituto de Salud Carlos III. Av/Monforte de Lemos, 5, 28029, Madrid, Spain; Epidemiology Section, Public Health Division, Department of Health of Madrid, Madrid, Spain. C/San Martín de Porres, 6, 28035, Madrid, Spain.

Pilar Amiano (P)

Consortium for Biomedical Research in Epidemiology & Public Health (CIBERESP), Instituto de Salud Carlos III. Av/Monforte de Lemos, 5, 28029, Madrid, Spain; Sub-Directorate for Public Health and Addictions of Gipuzkoa, Ministry of Health of the Basque Government, 20013, San Sebastian, Spain; Epidemiology and Public Health Area, Biodonostia Health Research Institute, 20014, San Sebastian, Spain.

Inés Gómez-Acebo (I)

Consortium for Biomedical Research in Epidemiology & Public Health (CIBERESP), Instituto de Salud Carlos III. Av/Monforte de Lemos, 5, 28029, Madrid, Spain; Universidad de Cantabria - IDIVAL, 39011, Santander, Spain.

Adonina Tardón (A)

Consortium for Biomedical Research in Epidemiology & Public Health (CIBERESP), Instituto de Salud Carlos III. Av/Monforte de Lemos, 5, 28029, Madrid, Spain; Institute of Health Research of the Principality of Asturias (ISPA)/University of Oviedo, 03301, Oviedo, Spain.

María Grau-Pérez (M)

Department of Preventive Medicine and Public Health, Universidad Autónoma de Madrid/ IdiPAZ, 28049, Madrid, Spain; Cardiometabolic and Renal Risk Unit, Biomedical Research Institute INCLIVA, Valencia, Spain.

Tamara García-Barrera (T)

Department of Chemistry, Faculty of Experimental Sciences, Campus El Carmen, University of Huelva. Research Center for Natural Resources, Health and the Environment, Campus El Carmen, University of Huelva, Av. del Tres de Marzo, 3, 21007, Huelva, Spain.

Manolis Kogevinas (M)

Consortium for Biomedical Research in Epidemiology & Public Health (CIBERESP), Instituto de Salud Carlos III. Av/Monforte de Lemos, 5, 28029, Madrid, Spain; Instituto de Salud Global de Barcelona (ISGlobal), 08003, Barcelona, Spain; Hospital del Mar Medical Research Institute (IMIM), 08003, Barcelona, Spain.

Marina Pollán (M)

Department of Epidemiology of Chronic Diseases, National Center for Epidemiology, Instituto de Salud Carlos III, Av/Monforte de Lemos, 5, 28029, Madrid, Spain; Consortium for Biomedical Research in Epidemiology & Public Health (CIBERESP), Instituto de Salud Carlos III. Av/Monforte de Lemos, 5, 28029, Madrid, Spain.

Beatriz Pérez-Gómez (B)

Department of Epidemiology of Chronic Diseases, National Center for Epidemiology, Instituto de Salud Carlos III, Av/Monforte de Lemos, 5, 28029, Madrid, Spain; Consortium for Biomedical Research in Epidemiology & Public Health (CIBERESP), Instituto de Salud Carlos III. Av/Monforte de Lemos, 5, 28029, Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH